The USA Food and Drug Administration (FDA) has approvied carfilzomib for treating advanced multiple myeloma. Dr. David Siegel, lead investigator from the John Theurer Cancer Center, Hackensack University, USA, and his research team examined 266 "heavily-pretreated patients with relapsed and refractory multiple myeloma who received at least two prior therapies." Patients thus receiving carfilzomib twice weekly for 3-4 weeks exhibited significant responses (23.7%), median duration of response (7.8 months), and overal survival (median of 15.6 months). Dr. Siegel's team thus believes that these figrues indicate an acceptable safety profile.
More information about this study, along with two additionl trials discussing the effects of carfilzomib can be found here.
Study mentioned: Siegel DS et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Jul 25 [Epub ahead of print]. PMID 22833546
No comments:
Post a Comment